working-with-human-tissues-for-translational-cancer-research

Working with Human Tissues for Translational Cancer Research

Medical research for human benefit is greatly impeded by the necessity for human tissues and subjects. However, upon obtaining consent for human ...

University of Texas MD Anderson Cancer Center

BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma.

Jacob Austin-Breneman

Department of Surgical Oncology

University of Texas MD Anderson Cancer Center

Working with Human Tissues for Translational Cancer Research

Jacob Austin-Breneman

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Department of Surgical Oncology

University of Texas MD Anderson Cancer Center

Working with Human Tissues for Translational Cancer Research

Department of Surgical Oncology